Background Few data exist on the comparative safety and immunogenicity of different
COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection of …

Antibody responses to SARS-CoV-2 can be detected in most infected individuals 10–15 d
after the onset of COVID-19 symptoms. However, due to the recent emergence of SARS-CoV-…

Improved understanding and management of COVID-19, a potentially life-threatening disease,
could greatly reduce the threat posed by its etiologic agent, SARS-CoV-2. Toward this end…

Background The management of complex orthopedic infections usually includes a prolonged
course of intravenous antibiotic agents. We investigated whether oral antibiotic therapy is …

Background Some high-income countries have deployed fourth doses of COVID-19 vaccines,
but the clinical need, effectiveness, timing, and dose of a fourth dose remain uncertain. We …

Background The safety and immunogenicity profile of COVID-19 vaccines when administered
concomitantly with seasonal influenza vaccines have not yet been reported. We therefore …

Background Staphylococcus aureus bacteraemia is a common cause of severe community-acquired
and hospital-acquired infection worldwide. We tested the hypothesis that adjunctive …

Background Clostridium difficile infection causes severe complications and frequently recurs.
An extended-pulsed fidaxomicin regimen might facilitate sustained clinical cure by …

Background Development of an effective vaccine against the pathogenic blood-stage infection
of human malaria has proved challenging, and no candidate vaccine has affected blood-…

There is a clear requirement for an accurate SARS-CoV-2 antibody test, both as a complement
to existing diagnostic capabilities and for determining community seroprevalence. We …